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Abstract
Background: Fibromyalgia (FM) can coexist with Spondyloarthritis (SpA) leading to diagnostic and treatment
dilemmas, especially in the presence of enthesitis. With this study we aimed to estimate the prevalence of FM
in SpA and to compare the clinical/disease features and TNF inhibitors (TNFi) in patients with/without FM.
Method: FM was defined by a score = > 5/6 of the Fibromyalgia Rapid Screening Tool (FiRST). SpA patients
(according to the rheumatologist) and consecutively consulting in the day care hospital but also in the outpatient
clinic at the rheumatology department of a tertiary care university hospital were included.
Demographics, disease characteristics, activity and severity and TNFi treatment were compared in patients with and
without FM; retention rate of the first TNFi and associated factors were explored (Kaplan Meier and Cox regression).
Results: Of the 196 enrolled SpA patients, 42 (21.4 %) were positively screened for FM. No statistically significant
differences in the prevalence of FM were found with regard to the fulfillment of the ASAS criteria for peripheral/
axial SpA, nor with regard to the fulfillment of the imaging vs. clinical arm of the ASAS criteria. However, patients
with coexisting FM presented significantly with more enthesitis, higher disease activity (BASDAI and VAS) and
poorer function scores (BASFI). No differences were found with regard to the initiation of TNFi treatment (79.0 % vs.
70.0 %, respectively), but the retention rate of the first TNFi after 2 years was shorter in the group of patients with
FM (28.1 % (95 % CI 12.5-44.0) vs. 41.7 % (95 % CI 32.2-51.3), p = 0.01).
Conclusion: This study confirms that coexistent FM in SpA might impact the patient-reported outcome indices for
disease activity and function, and the retention rate of TNFi treatment.
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Background
Spondyloarthritis (SpA) is a disease that includes a
spectrum of chronic inflammatory entities involving the
axial skeleton (sacroiliac joints and spine) and the per-
ipheral joints, and sharing a number of clinical features
such as arthritis, enthesitis, uveitis, dactylitis, psoriasis,
and inflammatory bowel disease with a common genetic
background, the human leukocyte antigen (HLA) B27
[1–4]. In 2009, the Assessment of the Spondyloarthritis
International Society (ASAS) proposed a new set of
classification criteria with the aim of recognizing patients
with early axial SpA (axSpA) including for the first time
the imaging of the sacroiliac joints (SIJ) by magnetic res-
onance imaging (MRI) and abnormal C-reactive protein
(CRP) [5], and another set for SpA patients with predom-
inantly peripheral manifestations (e.g., peripheral arthritis,
enthesitis, and dactylitis) [6, 7]. The axSpA criteria allow
the classification of patients with chronic back pain lasting
for ≥3 months and occurring before 45 years of age,
through two arms: the imaging arm in which patients
present with sacroiliitis (either on radiographs or MRI)
plus at least one additional SpA feature, and the clinical
arm in which patients need to be HLA-B27 positive and
present with two or more SpA characteristics.
However, the clinical arm has been criticized and is
not well-recognized by our health authorities nor some
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colleagues, despite the fact that it has been fully vali-
dated [8]. The main argument for such criticism is that
this arm would allow the classification of SpA in patients
without any objective sign of inflammation (abnormal
CRP or presence of inflammatory lesions seen on MRI
of the SIJ) or structural damage in the SIJ seen on pelvic
radiographs [6, 9].
Indeed, although the ASAS criteria have been proven
to be highly specific with acceptable sensitivity both for
diagnosis and classifying SpA patients [10, 11], one
could consider it inappropriate to apply them as a diag-
nostic tool in the absence of objective signs of structural
damage or inflammation, due to the potential risk of
misdiagnosing or over-diagnosing SpA in patients with
other conditions (e.g., fibromyalgia (FM), especially in
the presence of enthesitis [12].
FM is a complex chronic condition of unknown eti-
ology being considered as a pain amplification syndrome
associated with a central nervous system sensitization
mechanism [13]. Its hallmark symptoms are chronic
widespread musculoskeletal pain and generalized tender
points, but other symptoms can be present, such as fa-
tigue, sleep alterations and stiffness leading to significant
physical disability and reduced quality of life [14, 15]. Its
prevalence has been estimated at around 2–7 % of the
general global population and is predominantly found in
women [13]. FM can frequently be associated with other
rheumatic diseases such as rheumatoid arthritis and
Sjögren syndrome [16], and some studies have reported
the prevalence of FM at 12.6–15.0 % in SpA, but studies
are sparse [16–18]. This FM-SpA association may pre-
sent diagnostic and treatment dilemmas because some
SpA symptoms (e.g., pain at entheses, fatigue, stiffness,
and tenderness) can be also found in FM [12, 19]. Few
data are available to date, but it has already been reported
that SpA patients with FM tend to present with higher
self-reported disease activity indices (i.e., Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI)) making
interpretation of disease activity and treatment re-
sponse in SpA patients with concomitant FM very
challenging [19–21].
In the absence of specific biomarkers for FM, diagnosis
can currently be performed using the American College
of Rheumatology (ACR) criteria (1990 ACR classification
of FM and the ACR 2010 and modified 2010 diagnostic
criteria (2011)) [14, 22, 23]. However, these criteria were
developed for research and classification purposes, and
are difficult to apply in daily practice because they are
time consuming and require some training to be imple-
mented [24]. Moreover, such criteria (i.e., ACR 1990) in-
tegrate tender points on physical examination that might
reflect enthesitis in patients with SpA. Therefore, with
the objective of identifying an easy and valid screening tool
to facilitate the identification of FM patients in clinical
practice and research, the self-reported Fibromyalgia Rapid
Screening Tool (FiRST) [25] was developed, which has
sensitivity of 90.5 % and specificity of 85.7 % [25] for the
identification of FM patients.
All the above prompted us to conduct this study
aiming to 1) estimate the prevalence of FM according to
the FiRST in a population of patients with SpA and to
compare the prevalence with regard to the arm fulfilled
within the axial criteria (i.e., the imaging and clinical
arms), and 2) compare the demographics/disease fea-
tures, and TNF inhibitor (TNFi) treatment in terms of
initiation and first TNFi retention rate, in patients with
and without FM, respectively.
Methods
Study design
The completion of the FiRST, BASDAI and Bath
Ankylosing Spondylitis Functional Index (BASFI) ques-
tionnaires were performed prospectively, and data on
demographics and disease features were retrospectively re-
trieved from the medical files.
Study population
Patients aged ≥18 years were included, who were diag-
nosed with SpA (according to the rheumatologist) and
were consecutively attending the day care hospital, but
also the outpatient clinic at the rheumatology depart-
ment of a tertiary care university hospital.
Data collection
FM was defined if the score was ≥5/6 in the FIRST ques-
tionnaire [25]. Medical files of each patient who com-
pleted the FiRST questionnaire were reviewed by two
external investigators. The following information was
collected: age, gender, smoking status (past, current,
never), body weight and height, and the date of SpA
diagnosis, all available items permitting the calculation
of the fulfilment of the ASAS criteria; BASDAI [26], glo-
bal visual analog scale (VAS) according to the patient,
presence and number of current swollen joints diagnosed
by a physician and CRP at the day of the visit were col-
lected, and severity of the disease evaluated at the time of
the visit using the BASFI [27]; SpA treatments since
disease onset including information on non-steroidal
anti-inflammatory drugs (NSAIDs), conventional disease-
modifying antirheumatic drugs (cDMARD), and the type
and number of TNFi, number of switches, start/end date
and reason for discontinuation for each TNFi. Information
on past or current use of psychotropic medications (i.e.,
myorelaxants, antidepressants, or anxiolytics), strong opi-
oids [28, 29], and history of depression were collected. No
imaging (i.e., ultrasound or MRI) was performed specific-
ally for this study.
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Ethics considerations
This study was not submitted to any ethical committee
because it was performed using data collected in routine
care. However, all patients gave their oral consent to use
their data for this present study (as stated by French na-
tional official procedures for non-interventional studies).
Missing data handling
In the case of missing information patients were contacted
by telephone to obtain such information. If CRP was not
available on the day of the visit, the last available CRP
measurement collected within the previous 6 months was
used. Furthermore, if any of the answers to the FiRST
questionnaire were missing, we only excluded the patients
for whom the missing answers did not allow us to deter-
mine their group (with/without FM), e.g., a patient who
positively answered three questions but did not answer
the last three questions.
Statistical analysis
Continuous variables were reported by their mean and
standard deviation (SD) and qualitative variables by fre-
quency and percentage. Statistical significance was set at
p <0.05. The analysis was performed with the statistical
software SAS 9.4.
Evaluation of the reliability of the FiRST questionnaire
was performed. It was evaluated in a subset of 22 pa-
tients in two consecutive visits. These patients had stable
disease ( BASDAI between two visits: 0.22 (±1.32)) and
no treatment changes. The average time between the
two visits was 22 weeks (± 7.68). Reliability of the FM
diagnosis according to the FiRST definition was assessed
by prevalence-adjusted bias-adjusted kappa statistics
(PABAK).
FM prevalence was estimated in the global SpA popu-
lation, but also with regard to the ASAS classification
criteria fulfilment (axial or peripheral) and to the ful-
filment of the imaging vs. clinical arm of the ASAS criteria
for axSpA. Demographics, disease characteristics, activity
and severity were compared in the FM+/FM– groups by
the t test and chi square (χ2) test, as appropriate.
The percentage of patients who were ever exposed to
a TNFi, the mean number of TNFi received, the mean
duration of the first TNFi treatment and the reasons for
discontinuation of each TNFi were assessed in the total
population and compared in the FM+ /FM– groups.
The retention rate of the first TNFi treatment in the
FM+/FM– groups was estimated by survival analysis
(Kaplan–Meier curves) and compared by the log-rank
test. The predisposing factors for discontinuation of
the first TNFi during the first 2 years were estimated by
Cox regression models first by univariate and thereafter
by multivariate analysis, including in the model only the
variables that had a p value <0.10 in the univariate
analysis, plus age and gender. Finally, the percentage of
patients who received ≥3 TNFi within 12 months
(switchers) in both groups was compared by the χ2 test.
Results
Of the 213 patients who completed the FiRST question-
naire, 196 were retained for our analysis: patients with-
out a confirmed diagnosis of SpA (n = 14) and patients
who incompletely answered the questionnaire (n = 3)
were excluded. The reliability of the FM diagnosis was
good, with a PABAK = 0.64 (95 % CI 0.314; 0.958). In
our SpA population, the prevalence of concomitant FM
was 21.4 % (42/196).
Fibromyalgia prevalence according to the ASAS
classification criteria
Figure 1 summarizes the prevalence of FM depending
on the ASAS classification criteria. Of the 196 patients
included in the analysis, 185 (94.4 %) met the ASAS
criteria (182 (98.4 %) and 3 (1.6 %) axial and peripheral,
respectively). For the ASAS criteria for axSpA, 150
patients (82.4 %) and 32 patients (17.6 %) fulfilled the
imaging and clinical arms, respectively.
Prevalence of concomitant FM was greater in the
group of patients not fulfilling the ASAS criteria, al-
though this difference was not statistically significant
(21.1 % vs. 30.0 %, not significant). More interestingly,
no differences in the prevalence of FM were observed in
the group of patients fulfilling the imaging and clinical
arms of the ASAS criteria for axSpA (21.3 % vs. 19 %,
not significant).
Demographics, disease characteristics, activity and
severity were compared in the FM+ and FM– groups (see
Table 1). These two groups were similar in terms of age,
mean age at disease onset and smoking status. However,
patients fulfilling the FM+ definition presented more fre-
quently with enthesitis (59.5 % vs. 39.0 %, p = 0.01), a
higher total BASDAI (4.7 (±2.3) vs. 2.6 (±1.9), p <0.01),
higher global VAS (5.9 (±2.4) vs. 3.0 (±2.5), p <0.01) and
higher BASFI (4.8 (±2.7) vs. 2.0 (±2.3), p <0.01). No
significant differences were found for treatment with non-
steroidal anti-inflammatory drugs (NSAIDs) and conven-
tional disease-modifying antirheumatic drugs (cDMARDs);
as expected, the percentage of patients with either history
of depression, or use of psychotropic medication or strong
opioids was significantly higher in the FM+ group (67 % vs.
35 %, p <0.01).
TNFi treatment
Table 2 summarizes TNFi treatment characteristics in
our population. The percentage of patients ever exposed
to TNFi did not differ between the FM+ vs. FM– groups
(79 % vs. 70 %, respectively, not significant), whereas the
percentage of switchers was significantly higher in the
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FM+ group (15.2 % vs. 4.0 %, p = 0.03). Mean duration of
the first TNFi was significantly shorter in the FM+ group
(1.7 (± 2.4) vs. 3.5 (± 4.0) years, p <0.01) (Table 2).
The retention rate of the first TNFi after 2 years was
significantly shorter in the FM+ group: 28.1 % (95 % CI
12.5; 44.0) (n = 9) vs. 41.7 % (95 % CI 32.2; 51.3) (n = 43)
of patients were still on TNFi treatment after 2 years in
the FM+ and FM– groups, respectively (p <0.01) (Fig. 2).
Univariate Cox analysis identified FM (hazard ratio
(HR) 1.8, 95 % CI 1.1; 3.0), peripheral involvement (HR
1.6, 95 % CI 1.0; 2.6) and history of depression or psy-
chotropic medications or strong opioids intake (HR 0.6,
95 % CI 0.4; 0.9) as associated factors for discontinuation
of the first TNFi; however, on multivariate analysis only
FM (HR 1.7, 95 % CI 1.0; 2.9) and peripheral involve-
ment (HR 1.6, 95 % CI 1.0; 2.6) were independently
associated with discontinuation of the first TNFi.
Reasons for discontinuation of each TNFi were
similar percentages in the two groups (p value not
significant), inefficacy being the most frequent rea-
son in the total population.
Discussion
To our best knowledge, this is the first study aiming to
evaluate the prevalence of FM in a population of pa-
tients with SpA with regard to the fulfilment of the
ASAS classification criteria, and our results show that
no differences were found between the imaging and clin-
ical arms of the ASAS criteria for axSpA. This finding is
an argument in favor of the validity of such criteria, par-
ticularly for the clinical arm, which is still not fully ac-
cepted by some members of the scientific community.
The phenotype of SpA patients with concomitant FM
was more frequently female and presented more fre-
quently with enthesitis, reporting greater disease activity
and poorer function scores. These results are consistent
with previous studies [16, 17, 20, 30, 31].
As SpA patients with coexisting FM frequently present
with a higher disease activity score, the evaluation of dis-
ease activity and treatment effect might be challenging,
and might lead to unnecessary initiation of a TNFi, dose
escalations or switches. In our study, the percentage of
patients initiating a TNFi did not differ in the FM+ and
Fig. 1 Fibromyalgia (FM) in spondyloarthritis depending on the Assessment of the Spondyloarthritis International Society (ASAS) classification
criteria and the arm fulfilled. FM+ fibromyalgia defined by the Fibromyalgia Rapid Screening Tool (FIRST) questionnaire (i.e., FIRST ≥5/6), XRay(+)
radiographic sacroiliitis, MRI(+) magnetic resonance imaging sacroiliitis, CRP(+) abnormal C-reactive protein (i.e., ≥6 mg/L)
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FM– group, but patients with concomitant FM+ disease
were more likely to switch to other TNFi treatments.
Moreover, the retention rate of the first TNFi was shorter
in the FM+ group and the presence of FM was independ-
ently associated with a first TNFi discontinuation. This
confirms that the existence of concomitant FM in SpA
might complicate the evaluation of treatment response
[19, 20], and suggests that coexistence of FM should be
carefully screened when initiating a TNFi and/or evaluat-
ing its treatment effect, especially in the presence of
Table 1 Demographic and disease characteristics of patients with and without fibromyalgia
Total number of patients Fibromyalgia+ Fibromyalgia– P
(n = 196) (n = 42) (n = 154)
Age, years 43.0 (12.6) 41.4 (10.2) 43.4 (13.13) 0.21
Gender, female 59 (30.1 %) 17 (40.5 %) 42 (27.3 %) 0.10
Age at disease onset, years 29.9 (11.9) 28.7 (9.3) 30.2 (12.5) 0.40
Smoking status, ever smoked 106 (55.8 %) 23 (56.1 %) 83 (55.7 %) 0.96
HLA B27-positive 157 (82.2 %) 35 (83.3 %) 122 (81.9 %) 0.83
Radiographic sacroiliitis 134 (70.2 %) 27 (67.5 %) 107 (70.9 %) 0.68
Magnetic resonance imaging evidence of
inflammatory lesions of the sacroiliac joints
88 (58.3 %) 20 (54.1 %) 68 (59.7 %) 0.55
Raised C-reactive protein* 39 (22.3 %) 8 (20.0 %) 31 (23.0 %) 0.69
Past history of, or current arthritis 72 (36.7 %) 12 (28.6 %) 60(39 %) 0.22
Past history of, or current enthesitis 85 (43.4 %) 25 (59.5 %) 60 (39 %) 0.01
Bath Ankylosing Spondylitis Disease
Activity Index total (0–10)
3.0 (2.2) 4.7 (2.3) 2.6 (1.9) <0.01
Global visual analog scale (0–10) 3.6 (2.8) 5.9 (2.4) 3.0 (2.5) <0.01
Bath Ankylosing Spondylitis Functional
Index (range 0–10)
2.6 (2.7) 4.8 (2.7) 2.0 (2.3) <0.01
History of depression 42 (23.2 %) 16 (41.0 %) 26 (18.3 %) <0.01
Past or current intake of psychotropic
medications** or strong opioids
82 (41.8 %) 28 (66.7 %) 54 (35.1 %) <0.01
Past or current intake of psychotropic medications
or strong opioids or history of depression
82 (41.8 %) 28 (66.7 %) 54 (35.1 %) <0.01
Non-steroidal anti-inflammatory drug intake, ever 193 (99.0 %) 42 (100.0 %) 151 (98.7 %) 1.00
Synthetic disease-modifying antirheumatic drug use, ever 104 (53.1 %) 23 (54.8 %) 81 (52.6 %) 0.80
All results are presented as mean ± SD for continuous variables or number (%) for categorical variables. Fibromyalgia + was defined as a Fibromyalgia Rapid
Screening Tool (FiRST) score ≥5/6. * ≥ 6 mg/L; **myorelaxants, antidepressants or anxiolytics
Table 2 TNF inhibitor (TNFi) treatment in patients with and without fibromyalgia
Total number of patients Fibromyalgia+ Fibromyalgia- P
(n = 196) (n = 42) (n = 154)
Patients who received at least one TNFi 141 (71.9 %) 33 (78.6 %) 108 (70.1 %) 0.28
Number of TNFi treatments 1.84 (1.0) 2.36 (1.1) 1.68 (0.9) <0.01
Switchers* 9 (6.5 %) 5 (15.2 %) 4 (3.8 %) 0.03
First TNFi
Mean duration of first TNFi treatment, years 3.0 (3.8) 1.7 (2.4) 3.5 (4.0) <0.01
Reason for TNFi discontinuation:
Inefficacy % 54 (69.2 %) 12 (54.6 %) 42 (75.0 %) 0.14
Toxicity % 4 (5.1 %) 2 (9.1 %) 2 (3.6 %) 0.76
Inefficacy + toxicity % 4 (5.1 %) 3 (13.6 %) 1 (1.8 %) 0.23
Others % 16 (20.5 %) 5 (22.7 %) 11 (19.6 %) 1.00
All results are presented as mean ± SD for continuous variables or number (%) for categorical variables. Fibromyalgia + was defined as a Fibromyalgia Rapid
Screening Tool (FiRST) score ≥5/6. *Patients who received ≥3 TNFi within ≤12 months
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peripheral and/or enthesitic symptoms and in the pres-
ence of very severe disease activity and patient-reported
scores. In this sense the FiRST questionnaire represents
an easy to use and valid tool that might be used in clinical
practice before starting a TNFi, in particular in patients
presenting with enthesitis.
Our study has some weaknesses but also some
strengths. First the diagnosis of FM according to the
rheumatologist was not collected. However, we verified
the external validity of the FiRST in this SpA setting by
confirming the greater use of psychotropic medication
or strong opioids, or the history of depression in the
group of patients positively screened as FM+ [32, 33].
Second, lower sensitivity of the FIRST when applied in
an SpA population compared to the original study (66 %
vs. 90 %) has been recently reported [34]; however, these
data were not available at the time the study started.
Furthermore we did not use the ACR criteria (1990 ACR
classification of FM [14] - modified 2010 preliminary
ACR criteria [22]) to validate our results on the preva-
lence of FM, but this was due to the complexity of
applying such criteria in a daily practice setting [23].
Finally, one could consider that the sample size of our
study was too small to draw definite conclusions, e.g., in
the evaluation of the retention rate of the first TNFi,
only nine patients were at risk after 18 months of follow
up in the FM+ group.
Nevertheless, our study also has some strengths. First,
our analyses were performed on a representative number
of SpA patients in daily practice. Furthermore, to the
best of our knowledge this is the first study aiming to
evaluate the prevalence of FM according to the fulfil-
ment of the ASAS classification criteria and its impact
on TNFi treatment.
Conclusions
In summary, the similar percentages of FM in the different
subgroups of the ASAS classification criteria might be a
good argument in favor of the validity of these criteria,
and in particular of the clinical arm. The coexistence of
FM might impact the score of the instrument used to
evaluate disease activity and severity, particularly in the
patient-reported scores, and therefore might complicate
the evaluation of treatment response. The implementation
of the FiRST questionnaire might be helpful in clinical
practice, especially in the presence of enthesitic symptoms.
Other studies aiming to prospectively evaluate the impact
of concomitant FM in SpA in the treatment effect of TNFi
should allow us to confirm (or not) our findings.
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